|By PR Newswire||
|February 3, 2014 07:02 AM EST||
WESTBOROUGH, Mass., Feb. 3, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President & CEO, Dr. Geert Cauwenbergh, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 11:30am EST. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi's sd-rxRNA® technology platform.
The presentation will be available on the "Investors" section of the Company's website, www.rxipharma.com.
The 16th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. The conference will take place February 10-11 at the Waldorf Astoria in New York City.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (OTCQX: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012. For more information, please visit www.rxipharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.
RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
SOURCE RXi Pharmaceuticals Corporation
Sep. 29, 2016 10:30 PM EDT Reads: 4,021
Sep. 29, 2016 10:15 PM EDT Reads: 2,786
Sep. 29, 2016 10:00 PM EDT Reads: 1,804
Sep. 29, 2016 09:45 PM EDT Reads: 3,126
Sep. 29, 2016 08:45 PM EDT Reads: 1,546
Sep. 29, 2016 08:45 PM EDT Reads: 2,209
Sep. 29, 2016 06:15 PM EDT Reads: 3,685
Sep. 29, 2016 06:00 PM EDT Reads: 1,537
Sep. 29, 2016 05:15 PM EDT Reads: 2,855
Sep. 29, 2016 05:15 PM EDT Reads: 1,583
Sep. 29, 2016 04:45 PM EDT Reads: 2,794
Sep. 29, 2016 04:45 PM EDT Reads: 3,446
Sep. 29, 2016 04:30 PM EDT Reads: 1,343
Sep. 29, 2016 04:30 PM EDT Reads: 1,962
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, provided tips on how to be successful in large scale machine learning...
Sep. 29, 2016 04:00 PM EDT Reads: 2,402